Navigation Links
China's Vice Premier, Li Keqiang, Visits Sinovac to Inspect H1N1 Vaccine Production Preparation

BEIJING, June 2 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading developer and provider of vaccines in China, announced today that China's Vice Premier, Li Keqiang, accompanied with State Councilor and Secretary of the State Council, Ma Kai; Head of General Administration of Quality Supervision, Inspection and Quarantine, Wang Yong; Minister of Ministry of Health, Chen Zhu; Vice Minister of Ministry of Science and Technology, Liu Yanhua; Mayor of City of Beijing, Guo Jinlong; and other delegate members visited Sinovac to inspect its production preparation for a vaccine against influenza A (H1N1). Li Keqiang also emphasized the importance of having a vaccine for influenza A (H1N1) and encouraged Sinovac to step up vaccine production.

At the end of May, the US Center for Disease Control began distributing the influenza A (H1N1) virus strain to manufacturers. Once Sinovac receives the strain, we will commence production immediately.

During the visit, Li Keqiang commented that vaccination plays a crucial role in preventing and controlling infectious diseases. He spoke positively about the country's prevention and control of the disease during the past month, and about the vital role Sinovac has to play in protecting against H1N1. He added that Sinovac is qualified manufacturer to produce influenza A (H1N1) vaccine and will be a very important force for the country in controlling the spread of this virus.

Chen Zhu, Minister of Ministry of Health, commented that Sinovac is a company which has social responsibility.

Mr. Weidong Yin, Chairman, President and CEO of Sinovac, commented, "We were excited to showcase to China's Vice Premier our significant progress towards the production of a vaccine against the influenza A (H1N1) virus. The visit by high-ranking national officials gives us confidence that the Chinese government recognizes our capabilities. We believe that we can play a significant role in providing vaccines against influenza A (H1N1) virus. Once we receive the virus strain, we can begin production immediately."

Sinovac initiated the preparatory activities for influenza A (H1N1) vaccine production at the end of April. In May 2009, Sinovac continued to work closely with various Chinese government authorities and other global health organizations in order to monitor the disease and evaluate strategies to control and prevent its transmission. As a member of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), Sinovac scientists attended the May 19th WHO/UN Meeting with Influenza A (H1N1) Vaccine Manufacturers, which was held in Geneva to update attendees on the global capacity of influenza vaccines and ensure that the vaccines will be available to developing countries.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's vaccine products include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), and Anflu(R) (influenza). Panflu(TM), Sinovac's pandemic influenza vaccine (H5N1), has already been approved for government stockpiling. Sinovac is developing vaccines for enterovirus 71, universal pandemic influenza, Japanese encephalitis vaccine, and human rabies vaccine. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccines.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward- looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

    For more information, please contact:

     Helen G. Yang
     Sinovac Biotech Ltd.
     Tel:  +86-10-8289-0088 x9871
     Fax:  +86-10-6296-6910

     Amy Glynn/Sara Pellegrino
     The Ruth Group
     Tel:   +1-646-536-7023/7002

     Janine McCargo
     The Ruth Group
     Tel:   +1-656-536-7033

SOURCE Sinovac Biotech Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Sinovac to Host Conference Call to Report First Quarter 2009 Financial Results
2. Sinovac Biotech Ltd. Files Annual Report on Form 20-F
3. Sinovac Initiates Preparatory Activities for Swine Flu Vaccine
4. Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables
5. Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results
6. Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2008 Financial Results
7. Sinovac Biotech Co. Ltd., Sinovacs Beijing Subsidiary, Obtains High-Tech Enterprise Status
8. Sinovac Receives GMP Certification for its New Filling and Packaging Production Facility
9. Sinovac Enters Veterinary Vaccine Market with Inactivated Rabies Vaccine
10. Sinovac Releases Statement on Healive Vaccine Suspension
11. Sinovac Reports Third Quarter 2008 Unaudited Financial Results
Post Your Comments:
(Date:6/27/2016)... GUELPH, ON , June 27, 2016 /PRNewswire/ - BIOREM ... it has been advised by its major shareholders, Clean ... LP, United States based venture ... common shares of Biorem (on a fully diluted, as ... for the disposition of their entire equity holdings in ...
(Date:6/27/2016)... , ... June 27, 2016 , ... Parallel 6 ... trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module which ... with the physician and clinical trial team. , Using the CONSULT module, patients and ...
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
Breaking Biology Technology:
(Date:6/22/2016)... BETHESDA, Md. , June 22, 2016  The American ... by Trade Show Executive Magazine as one of ... Summit on May 25-27 at the Bellagio in ... based on the highest percentage of growth in each of ... number of exhibiting companies and number of attendees. The 2015 ...
(Date:6/20/2016)... Securus Technologies, a leading provider of ... safety, investigation, corrections and monitoring announced that after ... secured the final acceptance by all three (3) ... Systems (MAS) installed. Furthermore, Securus will have contracts ... by October, 2016. MAS distinguishes between legitimate wireless ...
(Date:6/9/2016)... , June 9, 2016 ... deploy Teleste,s video security solution to ensure the safety of ... during the major tournament Teleste, an ... systems and services, announced today that its video security solution ... to back up public safety across the country. The ...
Breaking Biology News(10 mins):